Drug Profile
Research programme: respiratory syncytial virus vaccine - GenVec
Alternative Names: GV-2311; RSV vaccine - GenVecLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator GenVec
- Developer GenVec; National Institute of Allergy and Infectious Diseases
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections(In children, In infants, In neonates, Prevention) in USA (IM, Injection)
- 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
- 17 Nov 2014 The programme is still available for licensing